IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37216614.
- Also identified by DOI 10.14309/ajg.0000000000002332 and PMC identifier 11098450.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab. Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004). UST is a promising therapy for the treatment of refractory IMC.
Medical subject headings
- Colitis